United Therapeutics Corporation Moves Forward Towards a Phase I Study of Pluristem's PLX-PAD Cells for Pulmonary Arterial Hypertension

Published: Feb 26, 2013

HAIFA, Israel, Feb. 26, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that following favorable preclinical studies, United Therapeutics Corporation intends to begin a human Phase I clinical trial in Australia using Pluristem's PLacental eXpanded (PLX-PAD) cells in patients diagnosed with Pulmonary Arterial Hypertension (PAH) upon approval by the Australian regulatory authorities. Details of the proposed trial can be viewed at: http://www.clinicaltrials.gov/ct2/show/NCT01795950?term=United+Therapeutics+cell&rank=1

Back to news